Form 4: Aligos Therapeutics CEO Lawrence Blatt Acquires Stock Options
SEC Form 4 Filing
Aligos Therapeutics CEO Lawrence Blatt reports acquisition of stock options in the company.
Summary
- Lawrence Blatt, CEO of Aligos Therapeutics, reported a transaction on March 1, 2024, involving stock options.
- Blatt acquired 965,435 stock options with an exercise price of $1.13.
- These options vest in equal monthly installments over four years, starting March 1, 2024.
- The options are for common stock, with the same number of shares underlying the derivative security.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The vesting schedule suggests a long-term commitment from the CEO.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options by the CEO could positively impact shareholders if it leads to improved company performance.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of earliest transaction and Vesting Commencement Date for the stock options. |
| 03/04/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.